Tranexamic Acid in Dacryocystorhinostomy (TA-DCR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01221909
Recruitment Status : Unknown
Verified October 2010 by HaEmek Medical Center, Israel.
Recruitment status was:  Not yet recruiting
First Posted : October 15, 2010
Last Update Posted : October 15, 2010
Information provided by:
HaEmek Medical Center, Israel

September 18, 2010
October 15, 2010
October 15, 2010
December 2010
December 2012   (Final data collection date for primary outcome measure)
Duration of DCR surgery in minutes and amount of blood loss in milliliters during surgery. [ Time Frame: Blood loss will be measured at the end of DCR operation from the suction bowel. Duration of surgery will be caculated by registering time of operation start and end. ]
Same as current
No Changes Posted
Late onset postoperative epistaxis or periorbital hematoma [ Time Frame: 8 days ]
Same as current
Not Provided
Not Provided
Tranexamic Acid in Dacryocystorhinostomy
Single Dose Tranexamic Acid for Dacryocystorhinostomy

Single dose tranexamic acid (TA) before dacryocystorhinostomy (DCR) operation: a prospective, double blind, placebo controlled study.

The study hypothesis: TA in DCR might reduce the intraoperative and postoperative bleeding in DCR surgery, and might reduce the duration of the surgery.

Not Provided
Not Applicable
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Nasolacrimal Tract Obstruction
  • Drug: Tranexamic acid
    Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.
  • Drug: saline solution
    5cc saline solution
  • Experimental: Tranexamic acid single dose of 500mg
    Intervention: Drug: Tranexamic acid
  • Placebo Comparator: Saline
    Intervention: Drug: saline solution

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
December 2012
December 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • obstruction of nasolacrimal pathway
  • eligible for DCR surgery
  • 18 years of age or older

Exclusion Criteria:

  • warfarin treatment
  • renal insufficiency
  • pregnancy
  • mental retardation
  • tendency to bleed
  • thromboembolic disease
  • thrombophilia
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Daniel Briscoe, M.D., Chairperson of Ophthalmology Dept, EMC, Afula 18101, Israel
HaEmek Medical Center, Israel
Not Provided
Not Provided
HaEmek Medical Center, Israel
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP